Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly sues partner Valeant over Permax US liability costs

This article was originally published in Scrip

Executive Summary

Lillyis suing its partner, Valeant Pharmaceuticals International, for breach of contract, alleging that Valeant failed to share the cost of product liability claims arising from the withdrawal of the Parkinson's disease treatment pergolide (Permax). The lawsuit was filed on December 24th in the US District Court for the Southern District of Indiana. Permax was originally developed by Lilly, but the US rights were later granted to Valeant; in the suit Lilly claims that the agreement covered sharing costs of product liability claims "alleged to have been caused by use of Permax sold in the US". In 2007, the product was voluntarily pulled from the market because of the FDA’s concern over the history of a high rate of cardiac valvular disease (heart valve regurgitation; Scrip Online, March 30th, 2007). Valeant claimed the cost-sharing obligations would take effect "only if the product liability claim at issue was caused by Valeant’s misconduct", according to the suit, an interpretation that Lilly disputes. Lilly states in the suit that "Valeant breached the Lilly/Valeant agreement by failing to share costs, as required by the Lilly/Valeant agreement, associated with a product liability claim".

You may also be interested in...



ChemoCentryx cuts price to get $45M IPO away

ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).

Ampio raises $16.9M as it advances PhIII premature ejaculation drug

Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.

Money talks: Verastem leverages IPO to build cancer stem cell pipeline

Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel